Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6P158
UPID:
DHX57_HUMAN
Alternative names:
DEAH box protein 57
Alternative UPACC:
Q6P158; A2RRC7; Q53SI4; Q6P9G1; Q7Z6H3; Q8NG17; Q96M33
Background:
The Putative ATP-dependent RNA helicase DHX57, also known as DEAH box protein 57, plays a crucial role in RNA metabolism. As a probable ATP-binding RNA helicase, it is involved in the unwinding and remodeling of RNA structures, which is essential for RNA processing, editing, and ribosome biogenesis.
Therapeutic significance:
Understanding the role of Putative ATP-dependent RNA helicase DHX57 could open doors to potential therapeutic strategies. Its involvement in fundamental RNA processes makes it a potential target for interventions in diseases where RNA metabolism is disrupted.